Comparison of AFib ablation outcomes in GLP-1 drug users versus non-users reveals whether these metabolic drugs affect arrhythmia recurrence after cardiac ablation.
Key findingComparison of AFib ablation outcomes in GLP-1 drug users versus non-users reveals whether these meta
What the researchers found
Comparison of AFib ablation outcomes in GLP-1 drug users versus non-users reveals whether these metabolic drugs affect arrhythmia recurrence after cardiac ablation.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
US TriNetX database analysis from 2016-2022 comparing ablation outcomes between HFpEF and HFrEF patients.
How the study worked
In publication.
Who was studied
US patients with HFpEF or HFrEF undergoing AF ablation from the TriNetX database (2016-2022)
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Comparison of outcomes after ablation of atrial fibrillation in patients with heart failure with preserved versus reduced ejection fraction: a US retrospective cohort analysis.
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
Citation
Amin, Ahmed Mazen; Gadelmawla, Ahmed Farid; Najah, Qasi; Awashra, Ameer; Abdelsayed, Kerollos; Abdelazeem, Basel; Felpel, Kevin; Kaplan, Rachel M; Winterfield, Jeffrey. (2025). Comparison of outcomes after ablation of atrial fibrillation in patients with heart failure with preserved versus reduced ejection fraction: a US retrospective cohort analysis.. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing. https://doi.org/10.1007/s10840-025-02197-3